Imperial College London
Alternate

DrSanjayPopat

Faculty of Medicine, National Heart & Lung Institute

Reader in Cancer Medicine
 
 
 
//

Contact

 

+44 (0)20 7808 2132s.popat Website

 
 
//

Location

 

Royal Marsden HospitalThe Royal Marsden Hospital

//

Summary

 

Publications

Citation

BibTex format

@article{Banna:2022:10.1016/j.lungcan.2022.05.018,
author = {Banna, GL and Addeo, A and Zygoura, P and Tsourti, Z and Popat, S and Curioni-Fontecedro, A and Nadal, E and Shah, R and Pope, A and Fisher, P and Spicer, J and Roy, A and Gilligan, D and Gautschi, O and Janthur, W-D and Lopez-Castro, R and Roschitzki-Voser, H and Dafni, U and Peters, S and Stahel, RA},
doi = {10.1016/j.lungcan.2022.05.018},
journal = {LUNG CANCER},
pages = {77--83},
title = {A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial},
url = {http://dx.doi.org/10.1016/j.lungcan.2022.05.018},
volume = {169},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AU  - Banna,GL
AU  - Addeo,A
AU  - Zygoura,P
AU  - Tsourti,Z
AU  - Popat,S
AU  - Curioni-Fontecedro,A
AU  - Nadal,E
AU  - Shah,R
AU  - Pope,A
AU  - Fisher,P
AU  - Spicer,J
AU  - Roy,A
AU  - Gilligan,D
AU  - Gautschi,O
AU  - Janthur,W-D
AU  - Lopez-Castro,R
AU  - Roschitzki-Voser,H
AU  - Dafni,U
AU  - Peters,S
AU  - Stahel,RA
DO  - 10.1016/j.lungcan.2022.05.018
EP  - 83
PY  - 2022///
SN  - 0169-5002
SP  - 77
TI  - A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial
T2  - LUNG CANCER
UR  - http://dx.doi.org/10.1016/j.lungcan.2022.05.018
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000814794800004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL  - 169
ER  -
Download